Evidence map›Paper›PMID 38861305›Full record

ArticleFuture oncology (London, England)2024

Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide.

Benjamin H Lowentritt, Shawn Du, Carmine Rossi, Erik Muser, Ibrahim Khilfeh, Frederic Kinkead, Jill Korsiak, Patrick Lefebvre, Dominic Pilon, Neeraj Agarwal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Benjamin H LowentrittChesapeake Urology, Towson, MD 21204, USA.
Shawn DuJanssen Scientific Affairs, LLC, a Johnson & Johnson Company, Horsham, PA 19044, USA.
Carmine RossiAnalysis Group, Inc., Montréal, QC, H3B 0G7, Canada.
Erik MuserJanssen Scientific Affairs, LLC, a Johnson & Johnson Company, Horsham, PA 19044, USA.
Ibrahim KhilfehJanssen Scientific Affairs, LLC, a Johnson & Johnson Company, Horsham, PA 19044, USA.
Frederic KinkeadAnalysis Group, Inc., Montréal, QC, H3B 0G7, Canada.
Jill KorsiakAnalysis Group, Inc., Montréal, QC, H3B 0G7, Canada.
Patrick LefebvreAnalysis Group, Inc., Montréal, QC, H3B 0G7, Canada.
Dominic PilonAnalysis Group, Inc., Montréal, QC, H3B 0G7, Canada.
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

Funding

Janssen Scientific Affairs, LLC, a Johnson & Johnson Company
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantThiohydantoinsAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesSurvival RateTreatment OutcomeapalutamideThiohydantoinsandrogen deprivation therapyandrogen receptor signaling inhibitorsapalutamidecastration-sensitivemetastatic prostate cancersurvival

Identifiers

PMID38861305
PMCPMC11497945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.